#United States #Boston #REGENXBIO #RGX-202 #ASGCT

REGENXBIO at ASGCT 2026 Annual Meeting

REGENXBIO Inc. (Nasdaq: RGNX) is set to make a significant impact at the upcoming 2026 American Society of Gene & Cell Therapy Annual Meeting, scheduled from May 11 to May 15 in bustling Boston, Massachusetts. This annual gathering is one of the most awaited events in the field of gene therapy and will feature groundbreaking presentations reflecting REGENXBIO's commitment to advancing the capabilities of gene therapy.

Key Presentations to Watch

The meeting will include several oral presentations that highlight the company's latest advancements. One of the notable presentations will be by Dr. Metewo Selase Kosi Enuameh, who will discuss enhancements made to the manufacturing processes through the NAVXpress® platform. The details are as follows:

• - Topic: Advancing AAV manufacturability toolbox for early programs and beyond
• - Presenter: Dr. Metewo Selase Kosi Enuameh
• - Session: AAV Critical Quality Attributes
• - Date/Time: Thursday, May 14, 8:45 – 9:00 AM ET
• - Location: MCEC Room 204AB, Level 2

Another highlight will be the presentation by Dr. Aravindhan Veerapandiyan regarding RGX-202, a gene therapy program aimed at treating Duchenne muscular dystrophy (DMD):

• - Topic: RGX-202 Investigational gene therapy for Duchenne Muscular Dystrophy
• - Presenter: Dr. Aravindhan Veerapandiyan
• - Session: In vivo clinical trials in eye and muscle disorders
• - Date/Time: Friday, May 15, 4:30 – 4:45 PM ET
• - Location: MCEC Room 210ABC, Level 2

Innovative Poster Presentations

In addition to oral presentations, the company will showcase several poster presentations that illustrate their leadership in the gene therapy space. For instance:

• - Title: NVG82, a capsid engineered for enhanced outer retinal gene transfer when administered in the suprachoroidal space, demonstrates superior on-target activity compared to AAV8
• - Presenter: Dr. Brendan Lilley
• - Location: MCEC Exhibit and Poster Hall
• - Date/Time: Tuesday, May 12, 5:00 – 6:30 PM ET

Further details on other poster presentations covering various aspects of gene therapy research will be available on the company’s website.

About REGENXBIO Inc.

Since its establishment in 2009, REGENXBIO has been at the forefront of gene therapy innovation focusing on AAV (adeno-associated virus) technology. The company is committed to improving the lives of patients with rare diseases through next-generation therapies. Its pipeline includes notable investigational therapies such as RGX-202 for Duchenne muscular dystrophy and several others in collaboration with industry partners like AbbVie and Nippon Shinyaku.

The upcoming ASGCT 2026 meeting marks an essential opportunity for REGENXBIO to share its findings with the scientific community and discuss how these emerging therapies could redefine treatment paradigms for patients suffering from debilitating genetic disorders. As the meeting approaches, the anticipation builds for REGENXBIO’s contributions to this vital field.

For continuous updates and more detailed information, attendees and interested parties are encouraged to visit the company’s official website at www.regenxbio.com.